Cargando…

The development of CAR design for tumor CAR-T cell therapy

In recent years, the chimeric antigen receptor modified T cells (Chimeric antigen receptor T cells, CAR-T) immunotherapy has developed rapidly, which has been considered the most promising therapy. Efforts to enhance the efficacy of CAR-based anti-tumor therapy have been made, such as the improvemen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Dandan, Jin, Guoliang, Chai, Dafei, Zhou, Xiaowan, Gu, Weiyu, Chong, Yanyun, Song, Jingyuan, Zheng, Junnian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862632/ https://www.ncbi.nlm.nih.gov/pubmed/29568411 http://dx.doi.org/10.18632/oncotarget.24179

Ejemplares similares

iNKT: A new avenue for CAR-based cancer immunotherapy
por: Liu, Yilin, et al.
Publicado: (2022)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma
por: Zhang, Qing, et al.
Publicado: (2017)

CAR-T-Derived Extracellular Vesicles: A Promising Development of CAR-T Anti-Tumor Therapy
por: Pagotto, Sara, et al.
Publicado: (2023)

Seatbelts in CAR therapy: How Safe Are CARS?
por: Minagawa, Kentaro, et al.
Publicado: (2015)

Engineering switchable and programmable universal CARs for CAR T therapy
por: Liu, Delong, et al.
Publicado: (2019)

Rationally designed approaches to augment CAR-T therapy for solid tumor treatment
por: Zhu, Chaojie, et al.
Publicado: (2023)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

Recombinant oncolytic adenovirus armed with CCL5, IL-12, and IFN-γ promotes CAR-T infiltration and proliferation in vivo to eradicate local and distal tumors
por: Fang, Lin, et al.
Publicado: (2023)

The Anti-fibrosis drug Pirfenidone modifies the immunosuppressive tumor microenvironment and prevents the progression of renal cell carcinoma by inhibiting tumor autocrine TGF-β
por: Wang, Gang, et al.
Publicado: (2022)

Innovative CAR-T Cell Therapy for Solid Tumor; Current Duel between CAR-T Spear and Tumor Shield
por: Jo, Yuna, et al.
Publicado: (2020)

Bringing cell therapy to tumors: considerations for optimal CAR binder design
por: Smith, Richard
Publicado: (2023)

New development in CAR-T cell therapy
por: Wang, Zhenguang, et al.
Publicado: (2017)

CAR T Cells: A Snapshot on the Growing Options to Design a CAR
por: Holzinger, Astrid, et al.
Publicado: (2019)

Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy
por: Kilgour, Marisa K., et al.
Publicado: (2023)

CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy
por: Harrer, Dennis Christoph, et al.
Publicado: (2023)

Editorial: CAR T-Cell Therapies in Hematologic Tumors
por: Coscia, Marta, et al.
Publicado: (2020)

CAR T Cell Therapy for Pediatric Brain Tumors
por: Patterson, John D., et al.
Publicado: (2020)

CAR-T Therapies in Solid Tumors: Opportunities and Challenges
por: Guzman, Grace, et al.
Publicado: (2023)

CAR T-Cell Therapy in Children with Solid Tumors
por: Kulczycka, Marika, et al.
Publicado: (2023)

CAR-T Cell Therapy
por: Ahmad, Aamir
Publicado: (2020)

CAR-Macrophages and CAR-T Cells Synergistically Kill Tumor Cells In Vitro
por: Liu, Maoxuan, et al.
Publicado: (2022)

The Application of Nanobody in CAR-T Therapy
por: Bao, Chaolemeng, et al.
Publicado: (2021)

Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology
por: Watanabe, Keisuke, et al.
Publicado: (2018)

Universal CARs, universal T cells, and universal CAR T cells
por: Zhao, Juanjuan, et al.
Publicado: (2018)

Conventional CARs versus modular CARs
por: Feldmann, Anja, et al.
Publicado: (2019)

Development of CAR-T Cell Persistence in Adoptive Immunotherapy of Solid Tumors
por: Fan, Jiaqiao, et al.
Publicado: (2021)

Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and tumor microenvironment, overcoming multiple obstacles of CAR T therapy for solid tumors
por: Wang, Yufeng, et al.
Publicado: (2023)

Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy
por: Ruppel, Katharina Eva, et al.
Publicado: (2022)

Current Progress in CAR-T Cell Therapy for Solid Tumors
por: Ma, Shuo, et al.
Publicado: (2019)

Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy
por: Lindo, Lorenzo, et al.
Publicado: (2021)

CAR T Cell Therapy’s Potential for Pediatric Brain Tumors
por: Thomas, Pauline, et al.
Publicado: (2021)

Hurdles to breakthrough in CAR T cell therapy of solid tumors
por: Marofi, Faroogh, et al.
Publicado: (2022)

Current progress in CAR-T cell therapy for tumor treatment
por: Chen, Lei, et al.
Publicado: (2022)

Clinical Investigations of CAR-T Cell Therapy for Solid Tumors
por: Chen, Kun, et al.
Publicado: (2022)

Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma
por: Martínez Bedoya, Darel, et al.
Publicado: (2021)

Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
por: Albinger, Nawid, et al.
Publicado: (2021)

CAR T-Cell Therapy: Is CD28-CAR Heterodimerization Its Achilles’ Heel?
por: Ferreira, Leonardo M. R., et al.
Publicado: (2021)

318 Building A Better CAR: Improving CAR-T Trafficking in Cancer Therapy
por: Hong, Yeonsun, et al.
Publicado: (2022)

CAR T cell therapy becomes CHIC: “cytokine help intensified CAR” T cells
por: Thomas, Simone, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tqaqcq2ef2jepkrrjlupp0om3c